Journal of Medicinal Chemistry · 2012 · 95 citations · 25 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsBioinorganic ChemistryEnzyme InhibitionStructure-activity Relationship AnalysisStructure-metabolism RelationshipsCarbonic Anhydrase FunctionCarbonic Anhydrase InhibitorsCarbonic Anhydrase TargetsChemical Structure-activity RelationshipsMedicinal Chemistry ApplicationsMetabolic Stability ScreeningMetabolic Stability TestingStructure-activity Relationship Modeling
In this study, 20 metallocene-based compounds comprising extensive structural diversity were synthesized and evaluated as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. These compounds proved moderate to good CA inhibitors in vitro, with several compounds displaying selectivity for cancer-associated isozymes CA IX and CA XII compared to off-target CA I and CA II. Compound 6 was the most potent ferrocene-based inhibitor with K(i)s of 5.9 and 6.8 nM at CA IX and XII, respectively. A selection of key drug-like parameters comprising Log P, Log D, solubility, and in vitro metabolic stability and permeability were measured for two of the ferrocene-based compounds, regioisomers 1 and 5. Compounds 1 and 5 were found to have characteristics consistent with lipophilic compounds, however, our findings show that the lipophilicity of the ferrocene moiety is not well modeled by replacement with either a naphthyl or a phenyl moiety in software prediction tools.
25
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Charles C. Wykoff, Nigel Beasley, Peter H. Watson et al. · PubMed · 2000 · 1.3K citations
Medicine, Cancer Biology, Oncology +17
R. Scott Obach · Drug Metabolism and Disposition · 1999 · 1.2K citations
Siden Top, Anne Vessières, Guy Leclercq et al. · Chemistry - A European Journal · 2003 · 402 citations